{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:21:44Z","timestamp":1768249304261,"version":"3.49.0"},"reference-count":89,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2191,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1111\/j.1529-8019.2009.01260.x","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T17:51:23Z","timestamp":1251827483000},"page":"441-451","source":"Crossref","is-referenced-by-count":33,"title":["Clinical risk management of Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum"],"prefix":"10.1155","volume":"22","author":[{"given":"Sandra","family":"Knowles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2125.2006.02797.x","article-title":"Clinical risk management of herb-drug interactions","volume":"63","author":"De Smet","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB2","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Derm"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.sder.2007.09.006","article-title":"Approach to the acute generalized, blistering patient","volume":"26","author":"Carr","year":"2007","journal-title":"Sem Cut Med Surg"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB6","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB7","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome)","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2332\/allergolint.O-07-483","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006","volume":"56","author":"Yamane","year":"2007","journal-title":"Allergol Int"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Derm"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1445-5994.2005.00790.x","article-title":"Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case control study","volume":"46","author":"Lin","year":"2005","journal-title":"Intern Med"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2008.02.021","article-title":"Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"59","author":"Lee","year":"2008","journal-title":"J Am Acad Derm"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB14","first-page":"384","article-title":"Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction","volume":"49","author":"Lee","year":"2008","journal-title":"Singapore Med J"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB15","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1097\/00002030-200009290-00012","article-title":"Prevention of nevirapine-associated exanthema using slow dose escalation and\/or corticosteroids","volume":"14","author":"Barreiro","year":"2000","journal-title":"AIDS"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB16","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(05)66227-7","article-title":"Lamotrigine and toxic epidermal necrolysis","volume":"348","author":"Sachs","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0190-9622(84)80317-5","article-title":"Observations on drug-induced toxic epidermal necrolysis in Singapore","volume":"10","author":"Chan","year":"1984","journal-title":"J Am Acad Derm"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2008.01.021","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy","volume":"87","author":"Valeyrie-Allanore","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme major, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1067\/mjd.2003.107","article-title":"Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus?","volume":"48","author":"Mandelcom","year":"2003","journal-title":"J Am Acad Derm"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.autrev.2005.10.003","article-title":"Toxic epidermal necrolysis in systemic lupus erythematosus","volume":"5","author":"Horne","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB22","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2008.11.884","article-title":"Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole","author":"Wanat","year":"2009","journal-title":"J Am Acad Derm"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB26","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB27","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin-induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB28","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1535-7511.2008.00263.x","article-title":"Of race, ethnicity, and rash: the genetics of antiepileptic drug-induced skin reactions","volume":"8","author":"Miller","year":"2008","journal-title":"Epilepsy Currents"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenetics Genomics"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000102045","article-title":"Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity","volume":"215","author":"Dainichi","year":"2007","journal-title":"Dermatology"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB33","unstructured":"33.\u2002U.S. Food and Drug Administration. Information for healthcare professionals: carbamazepine. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124718.htm. Accessed July 7, 2009."},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB34","doi-asserted-by":"crossref","unstructured":"34.\u2002 Chen YC , Chu CY , Hsiao CH . Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. JEADV 2008: published ahead of print.","DOI":"10.1111\/j.1468-3083.2008.02988.x"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clindermatol.2007.01.001","article-title":"In the pursuit of classifying severe cutaneous adverse reactions","volume":"25","author":"Wolf","year":"2007","journal-title":"Clin Dermatology"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous-membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/07853890701753664","article-title":"Stevens-Johnson syndrome: pathogenesis, diagnosis, and management","volume":"40","author":"Hazin","year":"2008","journal-title":"Ann Medicine"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/ICO.0b013e31802eb264","article-title":"Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes and management","volume":"26","author":"Chang","year":"2007","journal-title":"Cornea"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB41","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ophtha.2004.11.035","article-title":"Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome","volume":"112","author":"Di Pascuale","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB42","doi-asserted-by":"crossref","first-page":"e1002","DOI":"10.1542\/peds.2006-2401","article-title":"Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series","volume":"119","author":"Ravin","year":"2007","journal-title":"Pediatrics"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors","volume":"119","author":"LeCleach","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB45","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archderm.1991.01680050095011","article-title":"T-cell subsets in drug-induced toxic epidermal necrolysis. possible pathogenic mechanism induced by CD8-positive T cells","volume":"127","author":"Miyauchi","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB46","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB47","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2008.06.003","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases","volume":"52","author":"Abe","year":"2008","journal-title":"J Dermatol Sci"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB49","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjo.2007.136796","article-title":"Association of Fas ligand gene polymorphism with Stevens-Johnson syndrome","volume":"92","author":"Ueta","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB51","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nature Medicine"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB52","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/nm1208-1311","article-title":"Saving the skin from drug-induced detachment","volume":"14","author":"Nickoloff","year":"2008","journal-title":"Nature Medicine"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB54","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","article-title":"Plasmapheresis in severe drug-induced toxic epidermal necrolysis","volume":"121","author":"Kamanbroo","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB55","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Derm"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB56","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s001340051063","article-title":"Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis","volume":"25","author":"Furubacke","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB57","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjps.2004.12.007","article-title":"Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report","volume":"58","author":"Lissia","year":"2005","journal-title":"Br J Plast Surg"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000637-199508000-00002","article-title":"Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage","volume":"35","author":"Bradley","year":"1995","journal-title":"Ann Plast Surg"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB59","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J Trauma"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB60","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00007611-199610000-00015","article-title":"Cyclophosphamide in the treatment of toxic epidermal necrolysis","volume":"89","author":"Frangogianni","year":"1996","journal-title":"South Med J"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004630-199709000-00008","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Murphy","year":"1997","journal-title":"Burn Care Rehabil"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Derm"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB67","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00128071-200607060-00004","article-title":"Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"7","author":"Mittmann","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.sder.2006.04.004","article-title":"Toxic epidermal necrolysis and intravenous immunoglobulin: a review","volume":"25","author":"Trent","year":"2006","journal-title":"Semin Cut Med Surg"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB72","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB73","first-page":"717","article-title":"Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases","volume":"21","author":"Meiss","year":"2006","journal-title":"JEADV"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB74","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB75","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB76","unstructured":"76.\u2002US National Institutes of Health. Study of a potential new treatment for patients with toxic epidermal necrolysis (TEN). Clinical Trials. 2009. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00372723. Accessed July 7, 2009."},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB77","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.BCR.0000150215.78220.79","article-title":"Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center","volume":"26","author":"Haber","year":"2005","journal-title":"J Burn Care Rehabil"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB78","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/bjo.2006.109124","article-title":"The natural history of Stevens-Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy","volume":"91","author":"de Rojas","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB79","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/archopht.126.8.1059","article-title":"Temporary sutureless amniotic membrane patch for acute alkaline burns","volume":"126","author":"Kheirkhah","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB80","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ophtha.2005.09.001","article-title":"Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement","volume":"113","author":"Kobayashi","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB81","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaapos.2007.04.020","article-title":"Amniotic membrane grafting for conjunctival and lid surface disease in the acute phase of toxic epidermal necrolysis","volume":"11","author":"Tandon","year":"2007","journal-title":"J AAPOS"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB83","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archderm.141.7.907","article-title":"Pseudoephedrine-induced toxic epidermal necrolysis","volume":"141","author":"Nagge","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB84","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","article-title":"Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption","volume":"62","author":"Kano","year":"2007","journal-title":"Allergy"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB85","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9120(00)00146-6","article-title":"A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes","volume":"33","author":"Neuman","year":"2000","journal-title":"Clin Biochem"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB86","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1365-4362.2001.01173-7.x","article-title":"Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization","volume":"40","author":"Kura","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB87","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/pgmj.75.889.680","article-title":"Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins","volume":"75","author":"Edwards","year":"1999","journal-title":"Postgrad Med J"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB88","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1172\/JCI113798","article-title":"Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk","volume":"82","author":"Shear","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1529-8019.2009.01260.x-BIB89","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00002018-200427070-00004","article-title":"Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis","volume":"27","author":"Mittmann","year":"2004","journal-title":"Drug Saf"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2009.01260.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2009.01260.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:57:39Z","timestamp":1671818259000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2009.01260.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2009.01260.x","relation":{},"ISSN":["1396-0296","1529-8019"],"issn-type":[{"value":"1396-0296","type":"print"},{"value":"1529-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}